A Phase 2 interventional study of LC350189 formulated capsule and Placebo in Gout and Hyperuricemia, sponsored by LG Chem. Completed at 34 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by LG Chem · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.
Among the 11 studies in Gout by LG Chem, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is the only one in phase 2, and was the 3rd registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 37 across the 11 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Gout by LG Chem, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LC350189 50mg, Once a day (QD)
Drug: LC350189 formulated capsule
LC350189 100mg, QD
Drug: LC350189 formulated capsule
LC350189 200mg, QD
Drug: LC350189 formulated capsule
Placebo, QD
Drug: Placebo
Xanthine Oxidase Inhibitor
Matching placebo
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84
sUA level was measured at Day 84
Time frame: Day 84
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84
sUA level was measured at Day 84
Time frame: Day 84
Maximum Percent Reduction in sUA (Serum Uric Acid) Level
sUA level was measured at Day 1, 14, 28, 56, and 84
Time frame: Up to Day 84
| Milestone | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo |
|---|---|---|---|---|
| Started | 34 | 38 | 37 | 34 |
| Completed | 30 | 32 | 34 | 32 |
| Not completed | 4 | 6 | 3 | 2 |
| Withdrew: Adverse event | 0 | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 1 |
| Withdrew: Other reasons | 0 | 1 | 0 | 0 |
sUA level was measured at Day 84
| Percentage of participants | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 | 47.1 | 44.7 | 62.2 | 2.9 |
sUA level was measured at Day 84
| Percentage of participants | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84 | 58.8 | 63.2 | 78.4 | 2.9 |
sUA level was measured at Day 1, 14, 28, 56, and 84
| Percentage of reduction in sUA | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo |
|---|---|---|---|---|
| Maximum Percent Reduction in sUA (Serum Uric Acid) Level | -46.67 ± 13.560 | -50.64 ± 19.127 | -66.79 ± 15.787 | -11.20 ± 8.814 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LC350189 50mg | 0/34 (0%) | 0/34 (0%) | 15/34 (44.1%) |
| LC350189 100mg | 0/38 (0%) | 0/38 (0%) | 13/38 (34.2%) |
| LC350189 200mg | 0/37 (0%) | 0/37 (0%) | 21/37 (56.8%) |
| Placebo | 0/34 (0%) | 0/34 (0%) | 8/34 (23.5%) |
| Event | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo |
|---|---|---|---|---|
| Gout flareMetabolism and nutrition disorders | 9/34 | 6/38 | 10/37 | 6/34 |
| Blood creatine phosphokinase increasedInvestigations | 1/34 | 2/38 | 6/37 | 1/34 |
| Coronavirus test positiveInvestigations | 2/34 | 0/38 | 0/37 | 0/34 |
| Back painMusculoskeletal and connective tissue disorders | 2/34 | 0/38 | 0/37 | 0/34 |
| Blood pressure increasedInvestigations | 0/34 | 1/38 | 2/37 | 0/34 |
| Transaminases increasedInvestigations | 0/34 | 0/38 | 2/37 | 0/34 |
| DiarrehoeaGastrointestinal disorders | 1/34 | 2/38 | 1/37 | 1/34 |
| HeadacheNervous system disorders | 0/34 | 2/38 | 0/37 | 0/34 |
| Age, Continuous(years) | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52.0 ± 9.60 | 56.6 ± 10.64 | 54.6 ± 10.66 | 55.4 ± 9.97 | 54.7 ± 10.28 |
| Sex: Female, Male(Participants) | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 2 | 5 | 9 |
| Male | 33 | 37 | 35 | 29 | 134 |
| Ethnicity (NIH/OMB)(Participants) | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 10 | 7 | 7 | 30 |
| Not Hispanic or Latino | 28 | 28 | 30 | 27 | 113 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LC350189 50mg | LC350189 100mg | LC350189 200mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 2 | 2 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 | 0 | 3 |
| Black or African American | 3 | 6 | 6 | 5 | 20 |
| White | 30 | 27 | 25 | 29 | 111 |
| More than one race | 0 | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in May 2021, 17 months.
Results were first posted in Dec 2025, 4 years 7 months after primary completion. A results delay was requested in Jan 2022.
Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 17 months is above that.
Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tigulixostat